Amira Elbendary
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amira Elbendary has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Manuel Valdebran
Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC, USA
13 shared publications - Dirk M. Elston
Medical University of South Carolina
9 shared publications - Abdallah Gad
Department of Internal Medicine, Texas Tech University Health Sciences Center, Odessa, Texas
6 shared publications - Mostafa Alfishawy
Infectious Diseases Consultants and Academic Researchers of Egypt IDCARE, Egypt
5 shared publications Dirk M. Elston
Department of Dermatology & Dermatological Surgery, Medical University of South Carolina, Charleston
4 shared publications- Mahmoud Nassar
Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA
4 shared publications
Latest Publications
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2323-2333
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial
Background: Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment. Objectives: Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids. Methods: This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels. Results: A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide. Conclusion: Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image
- 28 June 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (11) , 2323-2333
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial
Background: Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment. Objectives: Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post‐traumatic keloids. Methods: This randomized clinical trial was conducted on 28 adult patients with post‐traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels. Results: A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide. Conclusion: Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results. Trial Registration: ClinicalTrials.gov identifier: NCT07014280. image
- 17 March 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (2) , e70080
Pulsed Dye Laser Versus Carboxytherapy for the Treatment of Stria Rubra: A Randomized Clinical and Histopathological Study
Background: Pulsed Dye Laser (PDL) and carboxytherapy target the vascular component of Stria Rubra (SR), followed by a secondary rejuvenating effect. Objective: To compare the efficacy and safety of PDL and carboxytherapy for the treatment of SR. Materials & Methods: Twenty patients with SR were included in this study. Each patient received PDL to one randomly selected SR side and carboxytherapy to the other randomly selected SR side. Clinical outcome assessment was done using number of striae and maximum stria width, Vancouver Scar scale (VSS), Erythema index (EI), and histopathological evaluation. Results: Significant improvement in VSS, EI, and histopathological scoring was found after treatment with each modality, whether PDL or carboxytherapy. Comparison between both modalities revealed a non‐significant difference between PDL and carboxytherapy as regards VSS, EI, and histopathological scoring change. Histopathological analysis showed a significant increase of collagen and elastic fibres following PDL. Collagen fibres and perpendicular blood vessels increased significantly with carboxytherapy. PIH was encountered following PDL. Conclusion: Both PDL and carboxytherapy are effective for the treatment of SR. PDL is proposed to produce a better outcome as regards improving the texture of SR skin. The risk of pigmentation can be avoided by proper PDL dosage.
- 17 March 2026
- Published by Wiley in Photodermatology, Photoimmunology & Photomedicine
- Vol. 42 (2) , e70080
Pulsed Dye Laser Versus Carboxytherapy for the Treatment of Stria Rubra: A Randomized Clinical and Histopathological Study
Background: Pulsed Dye Laser (PDL) and carboxytherapy target the vascular component of Stria Rubra (SR), followed by a secondary rejuvenating effect. Objective: To compare the efficacy and safety of PDL and carboxytherapy for the treatment of SR. Materials & Methods: Twenty patients with SR were included in this study. Each patient received PDL to one randomly selected SR side and carboxytherapy to the other randomly selected SR side. Clinical outcome assessment was done using number of striae and maximum stria width, Vancouver Scar scale (VSS), Erythema index (EI), and histopathological evaluation. Results: Significant improvement in VSS, EI, and histopathological scoring was found after treatment with each modality, whether PDL or carboxytherapy. Comparison between both modalities revealed a non‐significant difference between PDL and carboxytherapy as regards VSS, EI, and histopathological scoring change. Histopathological analysis showed a significant increase of collagen and elastic fibres following PDL. Collagen fibres and perpendicular blood vessels increased significantly with carboxytherapy. PIH was encountered following PDL. Conclusion: Both PDL and carboxytherapy are effective for the treatment of SR. PDL is proposed to produce a better outcome as regards improving the texture of SR skin. The risk of pigmentation can be avoided by proper PDL dosage.
- Open Access
- 27 October 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (6) , 951-956
The Enigma of Paradoxical Reactions to Biological Therapies
The advent of targeted biological agents has revolutionized the treatment approach for immune-mediated inflammatory diseases (IMIDs) in rheumatology and dermatology. However, these agents can lead to paradoxical immune-mediated inflammatory reactions (PRs), presenting challenges in clinical management. This case series aims to demonstrate diverse PRs associated with biologic therapies in IMID patients, shedding light on their clinical manifestations and management strategies. Five cases of IMID patients receiving targeted biologic therapies who developed PRs were retrospectively analyzed. Clinical presentations, histopathological findings, and treatment outcomes were documented. The PRs observed included pityriasis rosea-like drug reactions, eczematous reactions, lichenoid drug eruptions, and fixed drug eruptions. Histopathological examination revealed characteristic patterns corresponding to each PR type. Management strategies involved discontinuation or switching of biologic agents, resulting in resolution of cutaneous manifestations. This case series underscores the importance of recognizing and managing PRs in IMID patients undergoing biologic therapy. Further research is warranted to elucidate underlying mechanisms and guide therapeutic decisions, particularly with the emergence of biosimilars and potential cross-reactivity concerns.
- 27 October 2025
- Published by Wolters Kluwer Health in Indian Dermatology Online Journal
- Vol. 16 (6) , 951-956
Open AccessThe Enigma of Paradoxical Reactions to Biological Therapies
The advent of targeted biological agents has revolutionized the treatment approach for immune-mediated inflammatory diseases (IMIDs) in rheumatology and dermatology. However, these agents can lead to paradoxical immune-mediated inflammatory reactions (PRs), presenting challenges in clinical management. This case series aims to demonstrate diverse PRs associated with biologic therapies in IMID patients, shedding light on their clinical manifestations and management strategies. Five cases of IMID patients receiving targeted biologic therapies who developed PRs were retrospectively analyzed. Clinical presentations, histopathological findings, and treatment outcomes were documented. The PRs observed included pityriasis rosea-like drug reactions, eczematous reactions, lichenoid drug eruptions, and fixed drug eruptions. Histopathological examination revealed characteristic patterns corresponding to each PR type. Management strategies involved discontinuation or switching of biologic agents, resulting in resolution of cutaneous manifestations. This case series underscores the importance of recognizing and managing PRs in IMID patients undergoing biologic therapy. Further research is warranted to elucidate underlying mechanisms and guide therapeutic decisions, particularly with the emergence of biosimilars and potential cross-reactivity concerns.
- Open Access
- 12 November 2024
- Published by Springer Nature in Lasers in Medical Science
- Vol. 39 (1) , 1-12
Combined fractional CO2 laser with topical tioconazole versus Q-switched Nd-YAG laser in the treatment of onychomycosis; a randomized comparative trial
Treatment of onychomycosis includes topical and systemic agents. However, prolonged use of oral treatment could cause adverse effects and topical antifungal agents have limited penetration. To compare the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole nail solution versus Q-switched 1064 Nd: YAG laser in the treatment of fingernail onychomycosis. This randomized comparative clinical trial was conducted on 13 patients (47 nails) with fingernail onychomycosis. Patients were randomized to receive either fractional CO2 laser combined with topical tioconazole or Q-Switched Nd: YAG 1064 nm laser every 2 weeks for 3 months followed by a 1-month follow up assessment. Onychomycosis severity index (OSI) score, Dermatology life Quality Index (DLQI) score, patient satisfaction score, dermoscopic evaluation and KOH examination were used for assessment of improvement. OSI showed improvement after treatment in both arms (from 16.17 to 10.92 in fractional CO2 arm ( p = 0.026) and 23.13 to 22.43 ( p = 0.92)). When comparing both groups OSI score significantly reduced in the fractional CO2 laser combined with tioconazole more than the Q-switched laser group (p = 0.002). The mean DLQI score significantly improved in both groups but no statistically significant difference between the two groups. Significant improvement in patient satisfaction score was noted in both groups. Mycological cure using KOH examination was detected in both groups (44.4% in the CO2 group and 56.5% in the Q-switched group) with no significant difference (P value < 0.05). Ruin pattern keratosis found to be the most dermoscopic pattern to be associated with poor OSI score improvement. Fractional CO2 laser combined with topical tioconazole is more efficient in treatment of onychomycosis than Q-Switched Nd: YAG 1064 nm laser group as regards clinical improvement but both have comparable effect on mycological cure. Their use as adjuvant treatment rather than alone is recommended to ensure mycological cure in onychomycosis.
- 12 November 2024
- Published by Springer Nature in Lasers in Medical Science
- Vol. 39 (1) , 1-12
Open AccessCombined fractional CO2 laser with topical tioconazole versus Q-switched Nd-YAG laser in the treatment of onychomycosis; a randomized comparative trial
Treatment of onychomycosis includes topical and systemic agents. However, prolonged use of oral treatment could cause adverse effects and topical antifungal agents have limited penetration. To compare the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole nail solution versus Q-switched 1064 Nd: YAG laser in the treatment of fingernail onychomycosis. This randomized comparative clinical trial was conducted on 13 patients (47 nails) with fingernail onychomycosis. Patients were randomized to receive either fractional CO2 laser combined with topical tioconazole or Q-Switched Nd: YAG 1064 nm laser every 2 weeks for 3 months followed by a 1-month follow up assessment. Onychomycosis severity index (OSI) score, Dermatology life Quality Index (DLQI) score, patient satisfaction score, dermoscopic evaluation and KOH examination were used for assessment of improvement. OSI showed improvement after treatment in both arms (from 16.17 to 10.92 in fractional CO2 arm ( p = 0.026) and 23.13 to 22.43 ( p = 0.92)). When comparing both groups OSI score significantly reduced in the fractional CO2 laser combined with tioconazole more than the Q-switched laser group (p = 0.002). The mean DLQI score significantly improved in both groups but no statistically significant difference between the two groups. Significant improvement in patient satisfaction score was noted in both groups. Mycological cure using KOH examination was detected in both groups (44.4% in the CO2 group and 56.5% in the Q-switched group) with no significant difference (P value < 0.05). Ruin pattern keratosis found to be the most dermoscopic pattern to be associated with poor OSI score improvement. Fractional CO2 laser combined with topical tioconazole is more efficient in treatment of onychomycosis than Q-Switched Nd: YAG 1064 nm laser group as regards clinical improvement but both have comparable effect on mycological cure. Their use as adjuvant treatment rather than alone is recommended to ensure mycological cure in onychomycosis.
- 19 January 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (6) , 563-567
A comparative study of histopathologic features in alopecia areata and pattern hair loss
Background: When peribulbar infiltrates are absent, other histopathologic findings are necessary to distinguish alopecia areata (AA) from pattern hair loss (PHL). The purpose of this study is to determine which histopathologic features are most useful for differentiation.Methods: A retrospective slide review was conducted of AA and PHL scalp biopsy specimens from 2014 to 2019 at a tertiary referral center.Results: Ninety‐six cases were retrieved, of which 38 were AA. Peribulbar infiltrates were identified in 24 AA (63.2%) cases. A catagen/telogen shift was observed more frequently in AA than PHL (25 cases, 65.5% vs. 10 cases, 17.2%; p ≤ 0.0001). Lymphocytes (4 cases, 10.5% vs. 1 case, 1.7%; p = 0.058) and melanin (25 cases, 65.8% vs. 5 cases, 8.6%; p ≤ 0.0001) in fibrous tracts were more common in AA. Apoptotic bodies within vellus hairs were more frequently identified in AA (32 cases, 84.2% vs. 37 cases, 63.8%; p = 0.030). Small dystrophic follicles were also more common in AA (16 cases, 42.1% vs. 1 case, 1.7%; p < 0.0001).Conclusions: Common features of AA other than peribulbar infiltrates include a catagen/telogen shift, melanin in fibrous tracts, and small dystrophic follicles. Practitioners should consider these features when distinguishing AA from PHL in specimens without peribulbar infiltrates. The retrospective design limits our ability to exclude multifactorial alopecia, such as telogen effluvium.
- 19 January 2023
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 50 (6) , 563-567
A comparative study of histopathologic features in alopecia areata and pattern hair loss
Background: When peribulbar infiltrates are absent, other histopathologic findings are necessary to distinguish alopecia areata (AA) from pattern hair loss (PHL). The purpose of this study is to determine which histopathologic features are most useful for differentiation.Methods: A retrospective slide review was conducted of AA and PHL scalp biopsy specimens from 2014 to 2019 at a tertiary referral center.Results: Ninety‐six cases were retrieved, of which 38 were AA. Peribulbar infiltrates were identified in 24 AA (63.2%) cases. A catagen/telogen shift was observed more frequently in AA than PHL (25 cases, 65.5% vs. 10 cases, 17.2%; p ≤ 0.0001). Lymphocytes (4 cases, 10.5% vs. 1 case, 1.7%; p = 0.058) and melanin (25 cases, 65.8% vs. 5 cases, 8.6%; p ≤ 0.0001) in fibrous tracts were more common in AA. Apoptotic bodies within vellus hairs were more frequently identified in AA (32 cases, 84.2% vs. 37 cases, 63.8%; p = 0.030). Small dystrophic follicles were also more common in AA (16 cases, 42.1% vs. 1 case, 1.7%; p < 0.0001).Conclusions: Common features of AA other than peribulbar infiltrates include a catagen/telogen shift, melanin in fibrous tracts, and small dystrophic follicles. Practitioners should consider these features when distinguishing AA from PHL in specimens without peribulbar infiltrates. The retrospective design limits our ability to exclude multifactorial alopecia, such as telogen effluvium.
- Open Access
- 21 September 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 521-530
Role of streptococcal infection in the etiopathogenesis of pityriasis lichenoides chronica and the therapeutic efficacy of azithromycin: a randomized controlled trial
The exact aetiology of pityriasis lichenoides chronica (PLC) remains unknown. While phototherapy is the most investigated therapeutic modality, azithromycin has been used scarcely. The aim of this study is to evaluate the therapeutic efficacy of azithromycin in the treatment of PLC compared to NB-UVB and evaluating the presence of streptococcal infection as a possible etiological factor in PLC patients. The study was designed as a randomised controlled trial. Twenty-four patients with PLC were randomly allocated into either azithromycin (n = 13, standard dose every 10 days) or NB-UVB (n = 11, thrice weekly) groups. End of study (EOS) was either complete clearance of lesions or a maximum of 8 weeks. Therapeutic efficacy was defined as percent reduction in lesions and was calculated for the rash as a whole, erythematous papules alone, and hypopigmented lesions alone and graded into complete, very-good, good, poor or no response. Anti-streptolysin O titre (ASOT), anti-deoxyribonuclease B titre (anti-DNaseB) and throat culture were evaluated at day 0. No significant difference existed between both groups as regards therapeutic efficacy. At EOS, NB-UVB achieved significantly more percent reduction in the extent of hypopigmented lesions and consequently in the rash as a whole (p = 0.001, p = 0.034, respectively). The extent of the rash as a whole was significantly less in the NB-UVB at EOS (p = 0.029, respectively). The effect of NB-UVB on hypopigmented lesions appeared early at week 4 of treatment. Only two patients, one from each group, relapsed during the 3 month follow-up. Evidence of recent streptococcal infection was present in 79% of the cases, mainly in the form of elevated ASOT (94.7%). It was significantly more encountered in young children (< 13 years) (p = 0.03) and was associated with more extent of erythematous papules and consequently with more extent of the rash as a whole (p = 0.05 and p = 0.01, respectively). It did not affect outcome of therapy at EOS. Azithromycin did not show more favorable response in patients with recent streptococcal infection. Therapeutic efficacy of azithromycin is comparable to NB-UVB in treatment of PLC; however, NB-UVB is superior in management of hypopigmented lesions. It is highly suggested that PLC could be a post streptococcal immune mediated disorder.Registration number: ClinicalTrials.gov, NCT03831269.
- 21 September 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 521-530
Open AccessRole of streptococcal infection in the etiopathogenesis of pityriasis lichenoides chronica and the therapeutic efficacy of azithromycin: a randomized controlled trial
The exact aetiology of pityriasis lichenoides chronica (PLC) remains unknown. While phototherapy is the most investigated therapeutic modality, azithromycin has been used scarcely. The aim of this study is to evaluate the therapeutic efficacy of azithromycin in the treatment of PLC compared to NB-UVB and evaluating the presence of streptococcal infection as a possible etiological factor in PLC patients. The study was designed as a randomised controlled trial. Twenty-four patients with PLC were randomly allocated into either azithromycin (n = 13, standard dose every 10 days) or NB-UVB (n = 11, thrice weekly) groups. End of study (EOS) was either complete clearance of lesions or a maximum of 8 weeks. Therapeutic efficacy was defined as percent reduction in lesions and was calculated for the rash as a whole, erythematous papules alone, and hypopigmented lesions alone and graded into complete, very-good, good, poor or no response. Anti-streptolysin O titre (ASOT), anti-deoxyribonuclease B titre (anti-DNaseB) and throat culture were evaluated at day 0. No significant difference existed between both groups as regards therapeutic efficacy. At EOS, NB-UVB achieved significantly more percent reduction in the extent of hypopigmented lesions and consequently in the rash as a whole (p = 0.001, p = 0.034, respectively). The extent of the rash as a whole was significantly less in the NB-UVB at EOS (p = 0.029, respectively). The effect of NB-UVB on hypopigmented lesions appeared early at week 4 of treatment. Only two patients, one from each group, relapsed during the 3 month follow-up. Evidence of recent streptococcal infection was present in 79% of the cases, mainly in the form of elevated ASOT (94.7%). It was significantly more encountered in young children (< 13 years) (p = 0.03) and was associated with more extent of erythematous papules and consequently with more extent of the rash as a whole (p = 0.05 and p = 0.01, respectively). It did not affect outcome of therapy at EOS. Azithromycin did not show more favorable response in patients with recent streptococcal infection. Therapeutic efficacy of azithromycin is comparable to NB-UVB in treatment of PLC; however, NB-UVB is superior in management of hypopigmented lesions. It is highly suggested that PLC could be a post streptococcal immune mediated disorder.Registration number: ClinicalTrials.gov, NCT03831269.
- 26 March 2022
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 16 (4) , 102473
The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: A case-control study
- 26 March 2022
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 16 (4) , 102473
The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: A case-control study
- 9 November 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 63 (1) , 68-73
Hypopigmented lesions in pityriasis lichenoides chronica patients: Are they only post‐inflammatory hypopigmentation?
Background/Objectives: Pityriasis lichenoides chronica (PLC) lesions are reported to subside with post‐inflammatory hypopigmentation (PIH); hence, the most widely perceived nature of hypopigmented macules in PLC is PIH. However, to the best of our knowledge, no studies describing histopathological findings in these lesions are reported in literature. The aim of this study is to evaluate the hypopigmented lesions encountered in PLC patients and to shed light on their histopathological features.Methods: A cross‐sectional observational study included twenty‐one patients with PLC recruited in a period of twelve months. Clinical characteristics of each patient were collected. A skin biopsy from hypopigmented lesions whenever present was taken and assessed with routine haematoxylin and eosin stain.Results: Seventeen patients (81%) were less than 13 years old. Most patients (85.7%) demonstrated diffuse distribution of lesions. Hypopigmented lesions were present on the face in 12 (57.14%) patients. Histopathologically, hypopigmented lesions showed features of post‐inflammatory hypopigmentation in 19% of patients, residual PLC in 52.4% and active PLC 28.6% of patients.Conclusion: Hypopigmented lesions in PLC were noted mainly in younger ages, histopathologically they may show features of active or residual disease, beyond post‐inflammatory hypopigmentation. Consequently active treatment for patients presenting predominantly with hypopigmented lesions could be required to control the disease.
- 9 November 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 63 (1) , 68-73
Hypopigmented lesions in pityriasis lichenoides chronica patients: Are they only post‐inflammatory hypopigmentation?
Background/Objectives: Pityriasis lichenoides chronica (PLC) lesions are reported to subside with post‐inflammatory hypopigmentation (PIH); hence, the most widely perceived nature of hypopigmented macules in PLC is PIH. However, to the best of our knowledge, no studies describing histopathological findings in these lesions are reported in literature. The aim of this study is to evaluate the hypopigmented lesions encountered in PLC patients and to shed light on their histopathological features.Methods: A cross‐sectional observational study included twenty‐one patients with PLC recruited in a period of twelve months. Clinical characteristics of each patient were collected. A skin biopsy from hypopigmented lesions whenever present was taken and assessed with routine haematoxylin and eosin stain.Results: Seventeen patients (81%) were less than 13 years old. Most patients (85.7%) demonstrated diffuse distribution of lesions. Hypopigmented lesions were present on the face in 12 (57.14%) patients. Histopathologically, hypopigmented lesions showed features of post‐inflammatory hypopigmentation in 19% of patients, residual PLC in 52.4% and active PLC 28.6% of patients.Conclusion: Hypopigmented lesions in PLC were noted mainly in younger ages, histopathologically they may show features of active or residual disease, beyond post‐inflammatory hypopigmentation. Consequently active treatment for patients presenting predominantly with hypopigmented lesions could be required to control the disease.
- 30 October 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (7) , 874-876
Papillary eccrine adenoma presenting as a cutaneous horn
- 30 October 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (7) , 874-876
Papillary eccrine adenoma presenting as a cutaneous horn